Abstract
1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have